Facultative sterol uptake in an ergosterol-deficient clinical isolate of candida glabrata harboring a missense mutation in ERG11 and exhibiting cross-resistance to azoles and amphotericin B

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 8, 2012, Pages 4223-4232

  Hull, Claire M ^a   Parker, Josie E ^a   Bader, Oliver ^b   Weig, Michael ^b   Gross, Uwe ^b   Warrilow, Andrew G S ^a   Kelly, Diane E ^a   Kelly, Steven L ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CHOLESTANOL; CHOLESTEROL; DESMOSTEROL; ERGOSTA 7,22 DIENOL; ERGOSTEROL; FLUCONAZOLE; LANOSTEROL; LATHOSTEROL; MUTANT PROTEIN; STEROL; STEROL 14ALPHA DEMETHYLASE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA GLABRATA; CELL DENSITY; CROSS RESISTANCE; CULTURE MEDIUM; ERG11 GENE; FUNGAL GENE; FUNGUS GROWTH; GAS CHROMATOGRAPHY; HETEROLOGOUS EXPRESSION; LIPID ANALYSIS; MASS SPECTROMETRY; MINIMUM INHIBITORY CONCENTRATION; MISSENSE MUTATION; NONHUMAN; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; STEROL SYNTHESIS;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; AZOLES; BASE SEQUENCE; BIOLOGICAL TRANSPORT; CANDIDA GLABRATA; DRUG RESISTANCE, MULTIPLE, FUNGAL; ERGOSTEROL; FLUCONAZOLE; FUNGAL PROTEINS; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION, MISSENSE; PYRIMIDINES; SACCHAROMYCES CEREVISIAE; SEQUENCE ANALYSIS, DNA; STEROL 14-DEMETHYLASE; STEROLS; TRIAZOLES;

EID: 84864389183     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06253-11     Document Type: Article

References (41)

1. Bard M, et al. 2005. Sterol uptake in Candida glabrata: rescue of sterol auxotrophic strains. Diagn. Microbiol. Infect. Dis. 52:285-293. (Pubitemid 41297565)
2. Brockert PJ, et al. 2003. Phenotypic switching and mating type switching of Candida glabrata at sites of colonization. Infect. Immun. 71:7109-7118. (Pubitemid 37475343)
3. Brun S, et al. 2004. Mechanisms of azole resistance in petite mutants of Candida glabrata. Antimicrob. Agents Chemother. 48:1788-1796. (Pubitemid 38544390)
4. Chapeland-Leclerc F, et al. 2010. Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient. Antimicrob. Agents Chemother. 54:1360-1362.
5. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts (M27-A3), 3rd ed. CLSI, Wayne, PA.
6. Ellis D. 2002. Amphotericin B: spectrum and resistance. J. Antimicrob. Chemother. 49:7-10. (Pubitemid 34162651)
7. Ferrari S, et al. 2009. Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence. PLoS Pathog. 5:e1000268. doi:10.1371/journal.ppat.1000268.
8. Fidel PL, Jr, Vasquez JA, Sobel JD. 1999. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin. Microbiol. Rev. 12:80-96. (Pubitemid 29055954)
9. Gachotte D, et al. 1997. A yeast sterol auxotroph (erg25) is rescued by addition of azole antifungals and reduced levels of heme. Proc. Natl. Acad. Sci. U. S. A. 94:11173-11178. (Pubitemid 27450970)
10. Geber A, et al. 1995. Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility. Antimicrob. Agents Chemother. 39:2708-2717.
11. Groeneveld P, Rolley N, Kell DB, Kelly SL, Kelly DE. 2002. Metabolic control analysis and engineering of the yeast sterol biosynthetic pathway. Mol. Biol. Rep. 29:27-29. (Pubitemid 35021854)
12. Hazen KC, et al. 2005. Isolation of cholesterol-dependent Candida glabrata from clinical specimens. Diagn. Microbiol. Infect. Dis. 52:35-37. (Pubitemid 40692737)
13. Ishida N, et al. 1988. A single amino acid substitution converts cytochrome P45014DM to an inactive form, cytochrome P450SG1: complete primary structures deduced from cloned DNAs. Biochem. Biophys. Res. Commun. 155:317-323.
14. Joffrion TM, Cushion MT. 2010. Sterol biosynthesis and sterol uptake in the fungal pathogen Pneumocystis carinii. FEMS Microbiol. Lett. 311:1-9.
15. Kamran M, et al. 2004. Inactivation of transcription factor gene ACE2 in the fungal pathogen Candida glabrata results in hypervirulence. Eukaryot. Cell 3:546-552. (Pubitemid 38497992)
16. Kelly SL, Lamb DC, Corran AJ, Baldwin BC, Kelly DE. 1995. Mode of action and resistance to azole antifungals associated with the formation of 14α-methyl ergosta-8,24(28)-dien-3β,6α-diol. Biochem. Biophys. Res. Commun. 207:910-915.
17. Krakowiak PA, et al. 2003. Lathosterolosis: an inborn error of human and murine cholesterol synthesis due to lathosterol 5-desaturase deficiency. Hum. Mol. Genet. 12:1631-1641. (Pubitemid 36857309)
18. Krogh-Madsen M, Arendrup MC, Heslet L, Knudsen JD. 2006. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin. Infect. Dis. 42:938-944.
19. Lamb DC, et al. 1999. Purification, reconstitution, and inhibition of cytochrome P-450 sterol delta(22)-desaturase from the pathogenic fungus Candida glabrata. Antimicrob. Agents Chemother. 43:1725-1728. (Pubitemid 29331255)
20. Maesaki S, Marichal P, Vanden Bossche H, Sanglard D, Kohno S. 1999. Rhodamine 6G efflux for the detection of CDR1-overexpressing azole resistant Candida albicans strains. J. Antimicrob. Chemother. 44:27-31. (Pubitemid 29353679)
21. Mansfield BE, et al. 2010. Azole drugs are imported by facilitated diffusion in Candida albicans and other pathogenic fungi. PLoS Pathog. 6:e1001126. doi:10.1371/journal.ppat.1001126.
22. Martel CM, et al. 2010. A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14α-demethylase) and ERG5 (encoding C22-desaturase) is cross-resistant to azoles and amphotericin B. Antimicrob. Agents Chemother. 54:3578-3583.
23. Martel CM, et al. 2010. Identification and characterization of four azoleresistant erg3 mutants of Candida albicans. Antimicrob. Agents Chemother. 54:4527-4533.
24. Martel CM, et al. 2010. Complementation of a Saccharomyces cerevisiae ERG11/CYP51 (sterol 14 alpha-demethylase) doxycycline-regulated mutant and screening of the azole sensitivity of Aspergillus fumigatus isoenzymes CYP51A and CYP51B. Antimicrob. Agents Chemother. 54:4920-4923.
25. Nakayama H, Nakayama N, Arisawa M, Aoki Y. 2001. In vitro and in vivo effects of 14 alpha-demethylase (ERG11) depletion in Candida glabrata. Antimicrob. Agents Chemother. 45:3037-3045. (Pubitemid 32988825)
26. Nakayama H, et al. 2007. The Candida glabrata putative sterol transporter gene CgAUS1 protects cells against azoles in the presence of serum. J. Antimicrob. Chemother. 60:1264-1272. (Pubitemid 350168322)
27. Pfaller MA, et al. 2000. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob. Agents Chemother. 44:747-751. (Pubitemid 30117972)
28. Pfaller MA, Diekema DJ. 2004. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J. Clin. Microbiol. 42:4419-4431. (Pubitemid 39362350)
29. Pfaller MA, Diekema DJ. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20:133-163. (Pubitemid 46167771)
30. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Diekema DJ. 2002. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob. Agents Chemother. 46:1723-1727. (Pubitemid 34535188)
31. Roetzer A, Gabaldon T, Schuller C. 2011. From Saccharomyces cerevisiae to Candida glabrata in a few easy steps: important adaptations for an opportunistic pathogen. FEMS Microbiol. Lett. 314:1-9.
32. Russell DW. 2003. The enzymes, regulation, and genetics of bile acid synthesis. Annu. Rev. Biochem. 72:137-174. (Pubitemid 36930444)
33. Sanglard D, Ischer F, Bille J. 2001. Role of ATP-binding-cassette transporter genes in high-frequency acquisition of resistance to azole antifungals in Candida glabrata. Antimicrob. Agents Chemother. 45:1174-1183. (Pubitemid 32230999)
34. Sanguinetti M, et al. 2005. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob. Agents Chemother. 49:668-679. (Pubitemid 40175679)
35. Smith SJ, Parks LW. 1997. Requirement of heme to replace the sparking sterol function in the yeast Saccharomyces cerevisiae. Biochim. Biophys. Acta 1345:71-76. (Pubitemid 27105903)
36. Strushkevich N, Usanov SA, Park HW. 2010. Structural basis of human CYP51 inhibition by antifungal azoles. J. Mol. Biol. 397:1067-1078.
37. Tsai HF, et al. 2004. Candida glabrata erg1 mutant with increased sensitivity to azoles and to low oxygen tension. Antimicrob. Agents Chemother. 48:2483-2489.
38. Vandeputte P, et al. 2007. Reduced susceptibility to polyenes associated with a missense mutation in the ERG6 gene in a clinical isolate of Candida glabrata with pseudohyphal growth. Antimicrob. Agents Chemother. 51:982-990. (Pubitemid 46355284)
39. Vandeputte P, et al. 2009. Hypersusceptibility to azole antifungals in a clinical isolate of Candida glabrata with reduced aerobic growth. Antimicrob. Agents Chemother. 53:3034-3041.
40. Weiss A, Delproposto J, Giroux CN. 2004. High-throughput phenotypic profiling of gene-environment interactions by quantitative growth curve analysis in Saccharomyces cerevisiae. Anal. Biochem. 327:23-34. (Pubitemid 38367980)
41. Xiong QB, et al. 2005. Cholesterol import by Aspergillus fumigatus and its influence on antifungal potency of sterol biosynthesis inhibitors. Antimicrob. Agents Chemother. 49:518-524.